WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers...
OptimizeRx (NASDAQ:OPRX) reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences...
– Q1 revenue totals $19.8 million – Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively – 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance...
WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage...
WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and...
WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare...
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb...
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare...
- Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively...
- Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively...